From Iceland's woes, an $8B Actavis deal?

If Iceland's financial crisis was an earthquake, then this is a major aftershock: Actavis Group, one of the world's biggest generics makers, may go on the block for as much as $8 billion. Actavis is 80 percent-owned by Icelandic billionaire Thor Bjorgolfsson's private equity firm Novator. And Bjorgolfsson saw a big portion of his wealth go down the drain when Landsbanki Islands collapsed earlier this month.

Actavis had already hired Merrill Lynch to sift through its various options: sale, takeover, merger or public stock listing. Sources are now telling the Wall Street Journal that Bjorgolfsson's bank-related pain may push him to do a deal. A Novator spokesman said Actavis shareholders aren't looking to do a hasty deal, however. Any sale or merger wouldn't happen before next year, he said.

The global financial crisis could impede potential buyers, however. With companies strapped for credit, the M&A market has slowed considerably.

- read the WSJ article

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.